Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin
Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified · first‐line treatment of ovarian cancer
Weekly paclitaxel plus carboplatin showed no clear difference in neurological adverse event: Grade 3/4 neuropathy, not otherwise… compared with tri‐weekly paclitaxel plus carboplatin (low certainty).
1 finding from 1 review
- Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes onlyRR 1.12 [0.64, 1.94]4 studies · 3639 participantsLow